HTG Therapeutics is focused on utilizing its innovative technology platforms to create an entirely new generation of drug discovery tools aimed at developing therapeutic candidates with superior efficacy and safety profiles - transforming the process across a broad range of disease areas including oncology, immunology, diabetes, and rare diseases, among others.
HTG EdgeSeq and Epi-EdgeSeq technology enables a more highly resolved view of the transcriptome, especially aberrations in the physiological states leading to disease. By assimilating sophisticated RNA profiling and advanced medical chemistry technologies directly - and early-on - in the process, researchers can access critical learnings much sooner, significantly reduce risk, and increase successful outcomes.
On December 13, 2022 HTG hosted a key opinion leader (KOL) webinar on “The Role of RNA Profiling in Drug Discovery and Analysis”.
The webinar featured a presentation from KOL, Dr. Robert Spitale, PhD, University of California – Irvine, who discussed how RNA molecules can be used to understand the pharmaceutical drug effects on humans and help develop them towards more successful clinical use. The HTG Therapeutics team dove into the value of early pre-clinical insights that can be collected through their proprietary and comprehensive transcriptome-informed drug discovery platform.
On July 27, 2022 HTG hosted a key opinion leader (KOL) webinar on “Drug Candidate Attrition – How to Improve Clinical Development Success and Patient Outcomes”.
The webinar featured a presentation from KOL, Dr. Robert Spitale, PhD, University of California – Irvine, who discussed the use of RNA-based platform technologies in drug discovery. The HTG Therapeutics team introduced their proprietary transcriptome-informed drug discovery platform as the cornerstone of their differentiated and de-risked approach to small molecule drug discovery.
HTG Therapeutics leverages its transcriptomic and epi-transcriptomic profiling technology to dramatically transform the drug discovery process. HTG's platform currently produces a profile with nearly 42,000 data points per sample in three independent data sets and has the ability to detect changes in RNA modifiations, such as N6-methyladenosine (m6A), which has been increasingly implicated in various disease states.
By leveraging HTG's unique profiling technologies earlier in the drug discovery process, HTG Therapeutics is expected to generate lead compounds faster, and with superior efficacy and toxicity profiles.
HTG Therapeutics will identify development candidates targeting RNA and RNA-modifying proteins, targets relevant in a wide range of diseases of unmet therapeutic need. The profiling of these diseases using the HTG EdgeSeq technology is an essential element in guiding these efforts. From hit to lead clinical candidate- HTG seeks to bring to the forefront the power of transcriptome profiling and data science to generate insights factoring into the selection of improved therapeutic candidates entering clinical trials.
TUCSON, Ariz. , May 18, 2023 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023…
TUCSON, Ariz. , May 16, 2023 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business….
TUCSON, Ariz. , May 10, 2023 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights….
White Paper - Transcriptome-informed Drug Design: A Tale of Six Compounds
Download pdf 407KB
HTG Therapeutics White Paper HTP Proof of Concept
Download pdf 562KB
Page last updated April 10, 2023